In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

Lotte Biologics Co., the biotech arm of Lotte Group, said Thursday it has signed a deal with an Asia-based biotech company ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

4 As both T-DM1 and T-DXd differ in terms of their cytotoxic payloads, linker types, and drug-to-antibody ratios, scientists can directly compare how these variables affect the ADC’s efficacy and the ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical ...

Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...